Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SchistoShield vaccine in healthy adults
NCT05292391Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2022
- Primary completion
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Sm-p80 in schistosomiasis, sponsored by National Institute of Allergy and Infectious Diseases. Started May 2022; status: completed.
02
Drugs
Sm-p80
03
Conditions
schistosomiasis
Beyond the preview
Go deeper on NCT05292391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05292391.